Testosterone Effects on Insulin Sensitivity in Metabolic Syndrome

Phase 2, randomised, double-blind trial of testosterone in metabolic syndrome (3 arms), sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development. Primary endpoints: Insulin sensitivity at 13 weeks, Muscle and body fat distribution at 13 weeks and 3 more. Planned start May 2006; status: withdrawn.